Aneurysmal Subarachnoid Hemorrhage Drugs Market By Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics, Other Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

Aneurysmal Subarachnoid Hemorrhage Drugs Market

Aneurysmal subarachnoid hemorrhage (aSAH) is a condition in which brain aneurysm ruptures, resulting in bleeding in the subarachnoid space. In severe cases, bleeding may cause brain damage, which leads to paralysis, coma, or even death. The National Institutes of Health (NIH) stated that aSAH is a global health concern, with high fatality and permanent disability rates.

The main symptoms of aSAH include severe headache, nausea, vomiting, stiff neck, photophobia, blurred vision, loss of consciousness, and seizures. The diagnosis process of aSAH includes computed tomography (CT), lumbar puncture, angiogram, and magnetic resonance imaging (MRI).

The major factors that drives the global aSAH market are rise in prevalence of diseases such as stroke & hypertension, and surge in geriatric population. In addition, lifestyle that include increase in alcohol consumption and smoking increase risk of aSAH, which, in turn, stimulates the market growth. However, associated side effects of drugs and medication consumed during the treatment of aSAH restrain the market growth. Furthermore, increase in awareness regarding the treatment of aSAH is expected to provide numerous opportunities for the market growth in future.

The aSAH market is segmented on the basis of drug class and region. On the basis of drug class, the market is segmented into opioid analgesics, calcium channel blockers, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Depending on drug class, the calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market.

Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition, government initiatives, including the Precision Medicine and Affordable Care Act, along with well-planned reimbursement policies contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity increase demand for these devices. However, Asia-Pacific is expected to witness considerable market growth during the forecast period, due to rise in  government support to enhance healthcare infrastructure. Economic developments in countries, including India and China, with higher disposable incomes fuel the product demand .

The major players operating in the global aSAH drugs market are Azurity Pharmaceuticals, Johnson & Johnson, MediCure, NeurOp, Orexo AB, Pfizer, Inc., Pharmaxis, Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Vitrais, Inc. These players adopted product launch, collaboration, and merger & acquisition as their key developmental strategies.

KEY BENEFITS FOR STAKEHOLDERS

 The report provides in-depth analysis of the global ASAH Drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.

 It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.

A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global ASAH Drugs market growth.

KEY MARKET SEGMENTS

#By Drug Class

    ##Opioid Analgesic

    ##Calcium Channel Blocker

    ## Anticonvulsant

    ##Stool Softener

    ##Osmotic agents/diuretics

    ##Other Drugs 

Scope of Aneurysmal Subarachnoid Hemorrhage Drugs Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Opioid Analgesic

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Calcium Channel Blocker

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

4.4 Anticonvulsant

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market analysis by country

4.5 Stool Softener

4.5.1 Key market trends, growth factors and opportunities

4.5.2 Market size and forecast, by region

4.5.3 Market analysis by country

4.6 Osmotic Agents/Diuretics

4.6.1 Key market trends, growth factors and opportunities

4.6.2 Market size and forecast, by region

4.6.3 Market analysis by country

4.7 Other Drugs

4.7.1 Key market trends, growth factors and opportunities

4.7.2 Market size and forecast, by region

4.7.3 Market analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 North America

5.2.1 Key trends and opportunities

5.2.2 North America Market size and forecast, by Drug Class

5.2.3 North America Market size and forecast, by country

5.2.3.1 U.S.

5.2.3.1.1 Market size and forecast, by Drug Class

5.2.3.2 Canada

5.2.3.2.1 Market size and forecast, by Drug Class

5.2.3.3 Mexico

5.2.3.3.1 Market size and forecast, by Drug Class

5.3 Europe

5.3.1 Key trends and opportunities

5.3.2 Europe Market size and forecast, by Drug Class

5.3.3 Europe Market size and forecast, by country

5.3.3.1 Germany

5.3.3.1.1 Market size and forecast, by Drug Class

5.3.3.2 France

5.3.3.2.1 Market size and forecast, by Drug Class

5.3.3.3 United Kingdom

5.3.3.3.1 Market size and forecast, by Drug Class

5.3.3.4 Italy

5.3.3.4.1 Market size and forecast, by Drug Class

5.3.3.5 Rest of Europe

5.3.3.5.1 Market size and forecast, by Drug Class

5.4 Asia-Pacific

5.4.1 Key trends and opportunities

5.4.2 Asia-Pacific Market size and forecast, by Drug Class

5.4.3 Asia-Pacific Market size and forecast, by country

5.4.3.1 Japan

5.4.3.1.1 Market size and forecast, by Drug Class

5.4.3.2 China

5.4.3.2.1 Market size and forecast, by Drug Class

5.4.3.3 Australia

5.4.3.3.1 Market size and forecast, by Drug Class

5.4.3.4 India

5.4.3.4.1 Market size and forecast, by Drug Class

5.4.3.5 Rest of Asia-Pacific

5.4.3.5.1 Market size and forecast, by Drug Class

5.5 LAMEA

5.5.1 Key trends and opportunities

5.5.2 LAMEA Market size and forecast, by Drug Class

5.5.3 LAMEA Market size and forecast, by country

5.5.3.1 Brazil

5.5.3.1.1 Market size and forecast, by Drug Class

5.5.3.2 Turkey

5.5.3.2.1 Market size and forecast, by Drug Class

5.5.3.3 South Africa

5.5.3.3.1 Market size and forecast, by Drug Class

5.5.3.4 Rest of LAMEA

5.5.3.4.1 Market size and forecast, by Drug Class

6.1. Introduction

6.2. Top winning strategies

6.3. Product Mapping of Top 10 Player

6.4. Competitive Dashboard

6.5. Competitive Heatmap

6.6. Key developments

7.1 Azurity Pharmaceuticals

7.1.1 Company overview

7.1.2 Company snapshot

7.1.3 Operating business segments

7.1.4 Product portfolio

7.1.5 Business performance

7.1.6 Key strategic moves and developments

7.2 Johnson and Johnson

7.2.1 Company overview

7.2.2 Company snapshot

7.2.3 Operating business segments

7.2.4 Product portfolio

7.2.5 Business performance

7.2.6 Key strategic moves and developments

7.3 medicure

7.3.1 Company overview

7.3.2 Company snapshot

7.3.3 Operating business segments

7.3.4 Product portfolio

7.3.5 Business performance

7.3.6 Key strategic moves and developments

7.4 NeurOp

7.4.1 Company overview

7.4.2 Company snapshot

7.4.3 Operating business segments

7.4.4 Product portfolio

7.4.5 Business performance

7.4.6 Key strategic moves and developments

7.5 orexo ab

7.5.1 Company overview

7.5.2 Company snapshot

7.5.3 Operating business segments

7.5.4 Product portfolio

7.5.5 Business performance

7.5.6 Key strategic moves and developments

7.6 Pfizer, Inc.

7.6.1 Company overview

7.6.2 Company snapshot

7.6.3 Operating business segments

7.6.4 Product portfolio

7.6.5 Business performance

7.6.6 Key strategic moves and developments

7.7 Pharmaxis, Ltd.

7.7.1 Company overview

7.7.2 Company snapshot

7.7.3 Operating business segments

7.7.4 Product portfolio

7.7.5 Business performance

7.7.6 Key strategic moves and developments

7.8 Sun Pharmaceutical Industries Ltd.

7.8.1 Company overview

7.8.2 Company snapshot

7.8.3 Operating business segments

7.8.4 Product portfolio

7.8.5 Business performance

7.8.6 Key strategic moves and developments

7.9 teva pharmaceutical industries ltd.

7.9.1 Company overview

7.9.2 Company snapshot

7.9.3 Operating business segments

7.9.4 Product portfolio

7.9.5 Business performance

7.9.6 Key strategic moves and developments

7.10 Vitrais, Inc

7.10.1 Company overview

7.10.2 Company snapshot

7.10.3 Operating business segments

7.10.4 Product portfolio

7.10.5 Business performance

7.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 2. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OPIOID ANALGESIC, BY REGION , 2020-2030,($MILLION)

TABLE 3. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OPIOID ANALGESIC BY COUNTRY, 2020-2030,($MILLION)

TABLE 4. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR CALCIUM CHANNEL BLOCKER, BY REGION , 2020-2030,($MILLION)

TABLE 5. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET CALCIUM CHANNEL BLOCKER BY COUNTRY, 2020-2030,($MILLION)

TABLE 6. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR ANTICONVULSANT, BY REGION , 2020-2030,($MILLION)

TABLE 7. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET ANTICONVULSANT BY COUNTRY, 2020-2030,($MILLION)

TABLE 8. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR STOOL SOFTENER, BY REGION , 2020-2030,($MILLION)

TABLE 9. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET STOOL SOFTENER BY COUNTRY, 2020-2030,($MILLION)

TABLE 10. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OSMOTIC AGENTS/DIURETICS, BY REGION , 2020-2030,($MILLION)

TABLE 11. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OSMOTIC AGENTS/DIURETICS BY COUNTRY, 2020-2030,($MILLION)

TABLE 12. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET REVENUE, FOR OTHER DRUGS, BY REGION , 2020-2030,($MILLION)

TABLE 13. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET OTHER DRUGS BY COUNTRY, 2020-2030,($MILLION)

TABLE 14. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY REGION, 2020-2030,($MILLION)

TABLE 15. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 16. NORTH AMERICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 17. U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 18. CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 19. MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 20. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 21. EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 22. GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 23. FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 24. UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 25. ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 26. REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 27. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 28. ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 29. JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 30. CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 31. AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 32. INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 33. REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 34. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY DRUG CLASS, 2020-2030,($MILLION)

TABLE 35. LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET, BY COUNTRY, 2020-2030,($MILLION)

TABLE 36. BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 37. TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 38. SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 39. REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY DRUG CLASS 2020-2030,($MILLION)

TABLE 40.AZURITY PHARMACEUTICALS: COMPANY SNAPSHOT

TABLE 41.AZURITY PHARMACEUTICALS: OPERATING SEGMENTS

TABLE 42.AZURITY PHARMACEUTICALS: PRODUCT PORTFOLIO

TABLE 43.AZURITY PHARMACEUTICALS: NET SALES,

TABLE 44.AZURITY PHARMACEUTICALS: KEY STRATERGIES

TABLE 45.JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 46.JOHNSON AND JOHNSON: OPERATING SEGMENTS

TABLE 47.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 48.JOHNSON AND JOHNSON: NET SALES,

TABLE 49.JOHNSON AND JOHNSON: KEY STRATERGIES

TABLE 50.MEDICURE: COMPANY SNAPSHOT

TABLE 51.MEDICURE: OPERATING SEGMENTS

TABLE 52.MEDICURE: PRODUCT PORTFOLIO

TABLE 53.MEDICURE: NET SALES,

TABLE 54.MEDICURE: KEY STRATERGIES

TABLE 55.NEUROP: COMPANY SNAPSHOT

TABLE 56.NEUROP: OPERATING SEGMENTS

TABLE 57.NEUROP: PRODUCT PORTFOLIO

TABLE 58.NEUROP: NET SALES,

TABLE 59.NEUROP: KEY STRATERGIES

TABLE 60.OREXO AB: COMPANY SNAPSHOT

TABLE 61.OREXO AB: OPERATING SEGMENTS

TABLE 62.OREXO AB: PRODUCT PORTFOLIO

TABLE 63.OREXO AB: NET SALES,

TABLE 64.OREXO AB: KEY STRATERGIES

TABLE 65.PFIZER, INC.: COMPANY SNAPSHOT

TABLE 66.PFIZER, INC.: OPERATING SEGMENTS

TABLE 67.PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 68.PFIZER, INC.: NET SALES,

TABLE 69.PFIZER, INC.: KEY STRATERGIES

TABLE 70.PHARMAXIS, LTD.: COMPANY SNAPSHOT

TABLE 71.PHARMAXIS, LTD.: OPERATING SEGMENTS

TABLE 72.PHARMAXIS, LTD.: PRODUCT PORTFOLIO

TABLE 73.PHARMAXIS, LTD.: NET SALES,

TABLE 74.PHARMAXIS, LTD.: KEY STRATERGIES

TABLE 75.SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 76.SUN PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS

TABLE 77.SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 78.SUN PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,

TABLE 79.SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

TABLE 80.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 81.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS

TABLE 82.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 83.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,

TABLE 84.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES

TABLE 85.VITRAIS, INC: COMPANY SNAPSHOT

TABLE 86.VITRAIS, INC: OPERATING SEGMENTS

TABLE 87.VITRAIS, INC: PRODUCT PORTFOLIO

TABLE 88.VITRAIS, INC: NET SALES,

TABLE 89.VITRAIS, INC: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET SEGMENTATION

FIGURE 2.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030

FIGURE 3.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,BY DRUG CLASS,2020(%)

FIGURE 12.COMPARATIVE SHARE ANALYSIS OF OPIOID ANALGESIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CALCIUM CHANNEL BLOCKER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ANTICONVULSANT ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF STOOL SOFTENER ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OSMOTIC AGENTS/DIURETICS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER DRUGS ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030(%)

FIGURE 18.ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET BY REGION,2020

FIGURE 19.U.S. ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 20.CANADA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 21.MEXICO ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 22.GERMANY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 23.FRANCE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 24.UNITED KINGDOM ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 25.ITALY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 26.REST OF EUROPE ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 27.JAPAN ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 28.CHINA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 29.AUSTRALIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 30.INDIA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 31.REST OF ASIA-PACIFIC ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 32.BRAZIL ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 33.TURKEY ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 34.SOUTH AFRICA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 35.REST OF LAMEA ANEURYSMAL SUBARACHNOID HEMORRHAGE DRUGS MARKET,2020-2030($MILLION)

FIGURE 36. TOP WINNING STRATEGIES, BY YEAR

FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 39.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 40.COMPETITIVE DASHBOARD

FIGURE 41.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 42.AZURITY PHARMACEUTICALS.: NET SALES ,($MILLION)

FIGURE 43.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)

FIGURE 44.MEDICURE.: NET SALES ,($MILLION)

FIGURE 45.NEUROP.: NET SALES ,($MILLION)

FIGURE 46.OREXO AB.: NET SALES ,($MILLION)

FIGURE 47.PFIZER, INC..: NET SALES ,($MILLION)

FIGURE 48.PHARMAXIS, LTD..: NET SALES ,($MILLION)

FIGURE 49.SUN PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)

FIGURE 50.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ,($MILLION)

FIGURE 51.VITRAIS, INC.: NET SALES ,($MILLION